These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29021448)

  • 1. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.
    Namba M; Masuda T; Nakamura T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
    Intern Med; 2017 Dec; 56(24):3327-3331. PubMed ID: 29021448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.
    Ohara T; Oto T; Miyoshi K; Tao H; Yamane M; Toyooka S; Okazaki M; Date H; Sano Y
    Ann Thorac Surg; 2008 Dec; 86(6):e7-8. PubMed ID: 19021963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report.
    Chachaj A; Drozdz K; Chabowski M; Dziegiel P; Grzegorek I; Wojnar A; Jazwiec P; Szuba A
    Lymphology; 2012 Jun; 45(2):53-7. PubMed ID: 23057149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneovenous shunt for chylous ascites after lung transplantation for lymphangioleiomyomatosis.
    Kanou T; Nakagiri T; Minami M; Inoue M; Shintani Y; Okumura M
    Transplant Proc; 2012 Jun; 44(5):1390-3. PubMed ID: 22664021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide Use in Neonates: A Case Series.
    Zaki SA; Krishnamurthy MB; Malhotra A
    Drugs R D; 2018 Sep; 18(3):191-198. PubMed ID: 29948779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of Sirolimus for Lymphangioleiomyomatosis.
    Martirossian A; Shah S; Carrete L; Valle J; Valentine V
    Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
    Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
    Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphangioleiomyomatosis manifesting as refractory chylothorax and chyloperitoneum.
    Chen YS; Memon P
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midodrine, an Oral Alpha-1 Adrenoreceptor Agonist, Successfully Treated Refractory Congenital Chylous Pleural Effusion and Ascites in a Neonate.
    Tamaoka S; Osada A; Kin T; Arimitsu T; Hida M
    Chest; 2021 Apr; 159(4):e189-e191. PubMed ID: 34022016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneovenous shunt after failure of octreotide treatment for chylous ascites in lymphangioleiomyomatosis.
    Lefrou L; d'Alteroche L; Harchaoui Y; Franco D; Metman EH
    Dig Dis Sci; 2007 Nov; 52(11):3188-90. PubMed ID: 17638079
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of Propranolol in the Treatment of Chylous Effusions in Infants.
    Mitchell K; Weiner A; Ramsay P; Sahni M
    Pediatrics; 2021 Jul; 148(1):. PubMed ID: 34187907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of lymphangioleiomyomatosis found due to chylous ascites, pleural effusion and pelvic lymphadenopathy].
    Yano T; Hasizume I; Kasamatsu N; Kato T; Shibata M; Ashinuma N; Kobayashi K; Yasuda T; Nakamura A
    Nihon Kokyuki Gakkai Zasshi; 2007 May; 45(5):399-403. PubMed ID: 17554983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis.
    Barrera P; Simons SO; Luijk B; Wessels MJ; Heijdra YF
    Ann Am Thorac Soc; 2013 Aug; 10(4):408-9. PubMed ID: 23952870
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of octreotide in the treatment of chylothorax and chyloperitoneum.
    Pessotti CF; Jatene IB; Buononato PE; Elias PF; Pinto AC; Kok MF
    Arq Bras Cardiol; 2011 Aug; 97(2):e33-6. PubMed ID: 22002034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report.
    Berzigotti A; Magalotti D; Cocci C; Angeloni L; Pironi L; Zoli M
    Dig Liver Dis; 2006 Feb; 38(2):138-42. PubMed ID: 16389001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
    Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
    Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
    Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
    J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary lymphangiomyomatosis (LAM) developing chylothorax.
    Morimoto N; Hirasaki S; Kamei T; Horiike A; Miyatake H; Ogita Y; Nakano H
    Intern Med; 2000 Sep; 39(9):738-41. PubMed ID: 10969906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent occurrence of chylothorax, chylous ascites, and protein-losing enteropathy in systemic lupus erythematosus.
    Lee CK; Han JM; Lee KN; Lee EY; Shin JH; Cho YS; Koh Y; Yoo B; Moon HB
    J Rheumatol; 2002 Jun; 29(6):1330-3. PubMed ID: 12064855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.